Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions

Gan & Lee Pharmaceuticals Denmark Finland Germany Netherlands Sweden United Kingdom China New Jersey

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly treatment in patients with type 2 diabetes mellitus (T2DM), with significant HbA1c reductions alongside comprehensive benefits for body weight, blood pressure and blood lipid profiles.In a Phase 2b clinical trial, the bofanglutide injection showed superior HbA1c and body weight reduction than semaglutide (Ozempic®) after 24 weeks of bi-weekly treatment in patients with T2DM, along with an acceptable safety and tolerability profile.In a Phase 2 clinical trial, the once-weekly insulin GZR4 injection demonstrated comparable efficacy and safety profiles in patients with T2DM after 16 weeks of treatment. Notably, GZR4 injection achieved superior HbA1c reduction in patients with inadequate glycemic control on prior basal insulin therapy compared to once-daily insulin degludec (Tresiba®).View original content:https://www.prnewswire.co.uk/news-releases/gan--lee-pharmaceuticals-presented-multiple-results-in-novel-diabetes-therapies-at-the-american-diabetes-associations-85th-scientific-sessions-302487659.html

@ prnewswire.co.uk